Photodynamic Therapy Market

According to Stratistics MRC, the Global Photodynamic Therapy Market is accounted for $5.60 billion in 2023 and is expected to reach $15.36 billion by 2030 growing at a CAGR of 15.5% during the forecast period. In order to treat a variety of medical illnesses, including some forms of cancer and other non-cancerous conditions, photodynamic therapy (PDT) employs a combination of photosensitive medications and light. With the least amount of harm to the surrounding healthy tissue, it is a minimally invasive method that can be used to target and eliminate aberrant or malignant cells. Photodynamic therapy can be used to treat various conditions, including cancer, age-related macular degeneration (AMD), actinic keratosis, acne and other skin conditions

According to World Health Organization (WHO), Key facts updated in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Thus, the increasing prevalence of cancer cases across the globe is expected to rise the demand for photosensitizer drugs.



Market Dynamics:

Driver:

Rising rates of cancer and skin disorders

The demand for efficient treatment alternatives like PDT is driven by the increased incidence of cancer, particularly skin malignancies like basal cell carcinoma and squamous cell carcinoma. PDT's capacity to target cancer cells while limiting harm to healthy tissue becomes an important driver as cancer rates around the world continue to climb. In addition, PDT is viewed as a less invasive alternative to chemotherapy and standard surgery. The demand for PDT has grown as patients look for less invasive treatments with speedier recoveries and fewer side effects.

Restraint:

Competing therapeutic approaches and regulatory challenges

Depending on the medical situation, PDT frequently competes with other treatment techniques such surgery, chemotherapy, radiation therapy, and immunotherapy. The efficacy and drawbacks of these other treatments could threaten PDT's market share. For new photosensitive medications or PDT applications, regulatory approval procedures can be drawn-out and difficult. Market expansion might be slowed down and the range of PDT alternatives can be constrained by delays or challenges with obtaining regulatory licenses. Both healthcare professionals and patients may be discouraged from selecting PDT as a therapy option by inadequate insurance coverage or limitations on the circumstances under which PDT is covered which hampers the growth of the market.

Opportunity:

Modern imaging methods combined with personalized treatment methods

Individual patient characteristics may be taken into account while designing PDT treatments thanks to developments in personalized medicine and molecular testing. This method improves treatment results and patient satisfaction and offers a way to include precision medicine into PDT procedures. The accuracy of PDT treatments can be increased by improved imaging technologies that offer greater viewing of the targeted tissues. Fluorescence imaging and molecular imaging are two examples of recent advancements in imaging techniques that may offer prospects for more efficient intervention planning and monitoring thus creating wide range of opportunities for the growth of the market.

Threat:

High maintenance

One major issue with this treatment approach is the expensive expense of photodynamic therapy (PDT). PDT is expensive due to a number of factors, and these costs can change based on the illness being treated, the location, and the healthcare provider. Lasers or other types of light sources are needed for PDT in order to activate the photosensitizer. These gadgets can be expensive to buy and maintain. The photosensitive medications used in PDT can be costly to produce and may not be widely available thereby impedes the growth of the market.

Covid-19 Impact

Photodynamic Therapy (PDT), like other medical treatments and procedures, was significantly impacted by the COVID-19 pandemic. But since then, it's possible that the size and character of the influence on the PDT market have changed. The epidemic caused significant disruptions in the healthcare industry. These interruptions may have had an impact on PDT, which is frequently used to treat non-life-threatening diseases, causing delays in therapy. Disruptions in global supply chains may have had an impact on the manufacture and distribution of medical products, especially photosensitive medications used in PDT. This might have caused delays or shortages in getting necessary PDT components.

The photosensitizer drugs segment is expected to be the largest during the forecast period

The photosensitizer drugs segment is estimated to have a lucrative growth, as these are a crucial element of Photodynamic Therapy (PDT), a medical procedure that employs light-activated substances to target and eliminate aberrant or malignant cells, are photosensitizer medications, sometimes referred to as simply photosensitizers. These medications are an essential component of the PDT procedure because they allow for the selective death of target cells when they are subjected to particular light wavelengths. Drugs that act as photosensitizers are essential to the efficacy of PDT because they allow for targeted treatment with little harm to nearby healthy tissue. Achieving successful therapeutic results depends on choosing the right photosensitizer and optimizing the therapy parameters.

The systemic PDT segment is expected to have the highest CAGR during the forecast period

The systemic PDT segment is anticipated to witness the highest CAGR growth during the forecast period, as photosensitizer medication is injected intravenously in systemic photodynamic therapy (PDT), which allows it to circulate throughout the body and target cells systemically. This method is used to treat diseases like some forms of cancer that require extensive or deeply embedded aberrant cells. A promising method of treating some medical diseases that are difficult to target with regular PDT is systemic PDT. Widespread or deeply positioned lesions can be treated, and continuous research in the field is expanding its uses and enhancing its results. The precise medical problem and the patient's unique circumstances will determine the best course of treatment, whether it is traditional PDT or systemic PDT.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of significant companies in the United States, rising demand for new biologics for the treatment of cancer, a high rate of adoption of photodynamic therapy, and new product releases by market players. Moreover, as a result of an increase in product approvals by the US Food and Drug Administration, a surge in the use of photodynamic therapy for the treatment and management of actinic keratosis, and an increase in the number of cosmetologists offering photodynamic therapy.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to cancer cases and other illnesses that can be treated with PDT are on the rise in the Asia-Pacific region. PDT has been increasingly popular as a therapeutic option, particularly in nations like Japan, South Korea, China, and India. Age-related illnesses like age-related macular degeneration (AMD) and specific skin malignancies are more common due to the aging population in several Asia Pacific nations.



Key players in the market

Some of the key players profiled in the Photodynamic Therapy Market include Asieris Meditech Co., Ltd., Bausch Health Companies Inc., Biofrontera AG, Biolase, Inc, Biolitec AG, Boston Scientific Corporation, Candela Corporation , DUSA Pharmaceuticals, Galderma S.A., Lumibird (Quantel Medical), Modulight, Inc., PDT Pharmaceuticals, Photocure ASA, Photothera, Quest PharmaTech Inc., Soligenix, Sun Pharmaceutical Industries Limited and Theralase Technologies Inc.

Key Developments:

In May 2023, Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer. Asieris Pharmaceuticals will obtain exclusive global rights to UroViu’s patented technology of portable single-use cystoscope in the field of fluorescent imaging.

In August 2022, Asieris Pharmaceuticals announced its multinational Phase III Clinical Trial of Cevira(APRICITY), novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), has completed enrollment. Cevira is a breakthrough photodynamic drug-device combination product, based on the accumulation of a photosensitizer in the target cells.

Products Covered:
• Photosensitizer Drugs
• Photodynamic Therapy Devices
• Other Products

Indications Covered:
• Dermatological Conditions
• Ophthalmology
• Infectious Diseases
• Cancer
• Other Indications

Treatment Types Covered:
• Local PDT
• Systemic PDT
• Topical PDT

Applications Covered:
• Oncology
• Gynecology
• Gastroenterology
• Urology
• Dermatology
• Other Applications

End Users Covered:
• Hospitals
• Cosmetic and Dermatology Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances